MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.
Ginkgo Bioworks, a US-based microbe engineering services spinout of Massachusetts Institute of Technology, agreed to a reverse merger with special purpose acquisition company Soaring Eagle Acquisition Corp today, according to a regulatory filing.
The deal values Ginkgo at $15bn and includes a $775m private investment in public equity (Pipe) co-led by Baillie Gifford, Putnam Investments and Morgan Stanley Investment Management’s Counterpoint Global.
The Pipe financing also includes Ark Investment Management, Bain Capital’s public equity arm, Cascade Investment,…
